fluorouracil has been researched along with Cardiomyopathies, Primary in 27 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Following neoadjuvant chemotherapy for breast cancer, postoperative systemic therapy, also called post-neoadjuvant treatment, has been established in defined risk settings." | 6.72 | Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously? ( Baumann, R; Budach, W; Duma, MN; Dunst, J; Feyer, P; Fietkau, R; Haase, W; Harms, W; Hehr, T; Krug, D; Piroth, MD; Sauer, R; Sedlmayer, F; Souchon, R; Strnad, V, 2021) |
| "The 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) regimen is widely used in the management of breast cancer." | 4.95 | Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy. ( Abdulganieva, DI; Aliakberova, GI; Gylmanov, AA; Parve, S, 2017) |
| " The present study was aimed to assess cardiotoxicity of DLBS1425, compared to the mainstay regimen for breast cancer, 5-fluorouracil:doxorubicin:cyclophosphamide (FAC, given at 500/50/500 mg/m(2))." | 3.81 | Cardiovascular effects of Phaleria macrocarpa extracts combined with mainstay FAC regimen for breast cancer. ( Anggadiredja, K; Tjandrawinata, RR, 2015) |
| "Capecitabine plus oxaliplatin combination (XELOX) is the first-line treatment in metastatic colorectal cancer." | 3.78 | Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. ( Alì, G; Calabrese, R; Lenzi, P; Moretti, P; Orsucci, D; Petrozzi, L; Pizzanelli, C; Ricci, G; Siciliano, G, 2012) |
| "Two hundred and seventy-four consecutive patients with measurable metastatic breast cancer, without prior exposure to cytotoxic agents were treated with tamoxifen, 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)." | 3.67 | Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. ( Ames, F; Buzdar, AU; Carrasco, CH; Ewer, MS; Fraschini, G; Frye, D; Hortobagyi, GN; Hug, V; Mackay, B; Montague, E, 1989) |
| "Following neoadjuvant chemotherapy for breast cancer, postoperative systemic therapy, also called post-neoadjuvant treatment, has been established in defined risk settings." | 2.72 | Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously? ( Baumann, R; Budach, W; Duma, MN; Dunst, J; Feyer, P; Fietkau, R; Haase, W; Harms, W; Hehr, T; Krug, D; Piroth, MD; Sauer, R; Sedlmayer, F; Souchon, R; Strnad, V, 2021) |
| "Twenty females with disseminated breast cancer received courses of polychemotherapy with 21-day intervals." | 2.67 | [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin]. ( Bagdasarov, IuB; Min'kov, ED; Niu-Tian-de, GB; Odzharova, AA; Shkhvatsabaia, LV; Zaĭtseva, TI, 1994) |
| "Capecitabine is an orally administered prodrug that converts preferentially to 5-FU within tumors, resulting in enhanced concentrations of 5-FU in tumor tissue." | 2.49 | Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy. ( Endo, A; Nakashima, R; Takahashi, N; Tanabe, K; Yoshida, Y, 2013) |
| "Cardiotoxicity is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity." | 2.42 | Cardiotoxicity of cytotoxic drugs. ( Guchelaar, HJ; Richel, DJ; Schimmel, KJ; van den Brink, RB, 2004) |
| "Patients with malignancy may present with acute circulatory compromise requiring ICU monitoring and care." | 2.41 | Circulatory shock. ( Bogolioubov, A; Groeger, JS; Keefe, DL, 2001) |
| " Experimental studies suggest that this adverse effect could be due to myocardial accumulation of 5-FU leading to depletion of high energy phosphate compounds." | 1.28 | Acute myocardiotoxicity during 5-fluorouracil therapy. ( Escudier, B; Leclercq, B; Misset, B; Nitenberg, G; Rivara, D; Rougier, P, 1990) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (18.52) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 8 (29.63) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, MJ | 1 |
| Siddiqui, AA | 1 |
| Khan, AA | 1 |
| Ali, Z | 1 |
| Dewangan, RP | 1 |
| Pasha, S | 1 |
| Yar, MS | 1 |
| Piroth, MD | 1 |
| Krug, D | 1 |
| Sedlmayer, F | 1 |
| Duma, MN | 1 |
| Baumann, R | 1 |
| Budach, W | 1 |
| Dunst, J | 1 |
| Feyer, P | 1 |
| Fietkau, R | 1 |
| Haase, W | 1 |
| Harms, W | 1 |
| Hehr, T | 1 |
| Souchon, R | 1 |
| Strnad, V | 1 |
| Sauer, R | 1 |
| Parve, S | 1 |
| Aliakberova, GI | 1 |
| Gylmanov, AA | 1 |
| Abdulganieva, DI | 1 |
| Kounis, NG | 1 |
| Soufras, GD | 1 |
| Orsucci, D | 2 |
| Pizzanelli, C | 2 |
| Moretti, P | 2 |
| Siciliano, G | 2 |
| Endo, A | 1 |
| Yoshida, Y | 1 |
| Nakashima, R | 1 |
| Takahashi, N | 1 |
| Tanabe, K | 1 |
| Anggadiredja, K | 1 |
| Tjandrawinata, RR | 1 |
| Young, AC | 1 |
| Mercer, B | 1 |
| Perren, TJ | 1 |
| Dodwell, D | 1 |
| Alì, G | 1 |
| Calabrese, R | 1 |
| Ricci, G | 1 |
| Lenzi, P | 1 |
| Petrozzi, L | 1 |
| Schimmel, KJ | 1 |
| Richel, DJ | 1 |
| van den Brink, RB | 1 |
| Guchelaar, HJ | 1 |
| Rodríguez Roldán, JM | 1 |
| Lara Alvarez, MA | 1 |
| López Martínez, J | 1 |
| Díaz Abad, R | 1 |
| Caballero Campo, M | 1 |
| Del Nogal Sáez, F | 1 |
| Tsibiribi, P | 1 |
| Bui-Xuan, C | 1 |
| Bui-Xuan, B | 1 |
| Lombard-Bohas, C | 1 |
| Duperret, S | 1 |
| Belkhiria, M | 1 |
| Tabib, A | 1 |
| Maujean, G | 1 |
| Descotes, J | 1 |
| Timour, Q | 1 |
| Kawashiro, N | 1 |
| Kawana, M | 1 |
| Jurga, L | 2 |
| Mrinák, J | 1 |
| Ponist, J | 2 |
| Sefara, P | 1 |
| Berc, A | 2 |
| Min'kov, ED | 2 |
| Niu-Tian-de, GB | 1 |
| Shkhvatsabaia, LV | 1 |
| Bagdasarov, IuB | 1 |
| Zaĭtseva, TI | 1 |
| Odzharova, AA | 2 |
| Rexroth, G | 1 |
| Scotland, V | 1 |
| Cavalli, F | 1 |
| Lichinitser, MR | 1 |
| Vyshinskaia, GV | 1 |
| Nakhalova, TA | 1 |
| Garin, AM | 1 |
| Cheriparambil, KM | 1 |
| Vasireddy, H | 1 |
| Kuruvilla, A | 1 |
| Gambarin, B | 1 |
| Makan, M | 1 |
| Saul, BI | 1 |
| Bogolioubov, A | 1 |
| Keefe, DL | 1 |
| Groeger, JS | 1 |
| Ferrari, E | 1 |
| Taillan, B | 1 |
| Tibi, T | 1 |
| Darmon, JP | 1 |
| Gibelin, P | 1 |
| Chichmanian, RM | 1 |
| Dujardin, P | 1 |
| Morand, P | 1 |
| Speyer, JL | 1 |
| Green, MD | 1 |
| Sanger, J | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Kramer, E | 1 |
| Rey, M | 1 |
| Wernz, JC | 1 |
| Blum, RH | 1 |
| Hochester, H | 1 |
| Meyers, M | 1 |
| Misset, B | 1 |
| Escudier, B | 1 |
| Leclercq, B | 1 |
| Rivara, D | 1 |
| Rougier, P | 1 |
| Nitenberg, G | 1 |
| Hortobagyi, GN | 1 |
| Frye, D | 1 |
| Buzdar, AU | 2 |
| Ewer, MS | 1 |
| Fraschini, G | 1 |
| Hug, V | 1 |
| Ames, F | 1 |
| Montague, E | 1 |
| Carrasco, CH | 1 |
| Mackay, B | 1 |
| Thyss, A | 1 |
| Milano, G | 1 |
| Schneider, M | 1 |
| Demard, F | 1 |
| Jonás, P | 1 |
| Misurová, E | 1 |
| Marcus, C | 1 |
| Smith, TL | 1 |
| Blumenschein, GR | 1 |
6 reviews available for fluorouracil and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecit | 2021 |
Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiotoxicity; | 2017 |
Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathies; Colorectal Neoplasm | 2013 |
Cardiotoxicity of cytotoxic drugs.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; An | 2004 |
[Drugs which cause heart failure and cardiotoxicity].
Topics: Anthracyclines; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agen | 2007 |
Circulatory shock.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Anthracyclines; Antineoplastic Agents; Carcinoid Tu | 2001 |
3 trials available for fluorouracil and Cardiomyopathies, Primary
| Article | Year |
|---|---|
[An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Car | 1994 |
[Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Chemother | 1994 |
A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyclophosphamide | 1990 |
18 other studies available for fluorouracil and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cardiomyopathies; Cell Line, Tumor; Cell Proliferati | 2017 |
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
Topics: Cardiomyopathies; Deoxycytidine; Female; Fluorouracil; Humans; Neuromuscular Diseases; Organoplatinu | 2013 |
Reply to: Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
Topics: Cardiomyopathies; Deoxycytidine; Female; Fluorouracil; Humans; Neuromuscular Diseases; Organoplatinu | 2013 |
Cardiovascular effects of Phaleria macrocarpa extracts combined with mainstay FAC regimen for breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleeding | 2015 |
Anthracycline-induced cardiomyopathy in siblings with early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyclophos | 2011 |
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiomyopathies; Colo | 2012 |
[Myocardial necrosis and cardiogenic shock with normal coronaries: cardiotoxicity due to 5-FU or catecholamine cardiomyopathy].
Topics: Antimetabolites, Antineoplastic; Cardiomyopathies; Catecholamines; Coronary Angiography; Coronary Ve | 2006 |
Cardiac lesions induced by 5-fluorouracil in the rabbit.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cardiomyopathies; Coronary Disease; Electrocard | 2006 |
Non-invasive methods for detection of cardiomyopathy in the course of antineoplastic treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiomyopathies; Doxorubicin; Drug Therapy, Combination; F | 1982 |
[Cardiac toxicity of 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Cardiomyopathies; Cecal Neoplasms; Colonic Neoplasms; Death, Sudden | 1994 |
[The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovas | 1994 |
Acute reversible cardiomyopathy and thromboembolism after cisplatin and 5-fluorouracil chemotherapy--a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardiomyopathies; Cisplati | 2000 |
[Cardiac toxicity of fluoro-uracil. Typical and atypical aspects. Apropos of 8 cases].
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiomyopathies; Coronary Disease; Fluorouracil; Heart Diseases; | 1992 |
Acute myocardiotoxicity during 5-fluorouracil therapy.
Topics: Adult; Cardiomyopathies; Colonic Neoplasms; Fluorouracil; Hemodynamics; Humans; Infusions, Intraveno | 1990 |
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyc | 1989 |
Circulating drug levels in patients presenting cardiotoxicity to 5-FU.
Topics: Cardiomyopathies; Fluorouracil; Humans | 1988 |
[Monitoring cardiotoxicity during antineoplastic chemotherapy].
Topics: Adult; Cardiomyopathies; Doxorubicin; Fluorouracil; Heart Failure; Humans; Middle Aged | 1987 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |